[{"orgOrder":0,"company":"GoLiver Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GoLiver Therapeutics Receives Scientific Advice from EMA on its Clinical Development and Biomanufacturing Strategy for Acute Liver Failure","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cell therapy products","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"GoLiver Therapeutics","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"GoLiver Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GoLiver Th.."}]

Find Clinical Drug Pipeline Developments & Deals by GoLiver Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : European Medicines Agency (EMA) has given a positive scientific advice on its clinical development, pharmaco-toxicological and production strategy plans. With this positive scientific advice, GoLiver Ther...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 29, 2020

                          Lead Product(s) : Cell therapy products

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I/ Phase II

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank